ELSI Implications of Prioritizing Biological Therapies in Times of COVID-19

J Law Med Ethics. 2020 Sep;48(3):579-582. doi: 10.1177/1073110520958884.

Authors

Louise C Druedahl¹, Audrey Lebret¹, Timo Minssen¹

Affiliation

¹ Louise C. Druedahl, M.Sc.Pharm., is a Ph.D. candidate at CORS, University of Copenhagen. Audrey Lebret, LL.D., LL.M., MSc.M., is a postdoctoral researcher at CeBIL, University of Copenhagen. Timo Minssen, LL.D., LL.Lic., LL.M., M.I.C.L, Dipl. Jur. is Professor of Law and the Director of CeBIL, University of Copenhagen.

PMID: 33021187
DOI: 10.1177/1073110520958884

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Betacoronavirus
Biological Therapy
COVID-19
Coronavirus Infections*
Ethics, Research*
Humans
Pandemics*
Pneumonia, Viral*
SARS-CoV-2